Jennifer L Medlin1, Karen E Hansen2, Sara R Fitz3, Christie M Bartels2. 1. University of Wisconsin Hospital and Clinics, Madison, WI. 2. Department of Medicine, University of Wisconsin School of Medicine and Public Health, 1625 Highland Ave #4132, Madison, WI 53705. 3. Department of Dermatology, Medical Associates Clinic, Dubuque, IA.
Abstract
OBJECTIVES: Although systemic lupus erythematosus (SLE) most commonly occurs in reproductive-age women, some are diagnosed after the age of 50. Recognizing that greater than one-third of SLE criteria are cutaneous, we undertook a systematic review and meta-analysis to evaluate differences in cutaneous manifestations in early- and late-onset SLE patients. METHODS: We searched the literature using PubMed, CINAHL, Web of Science, and Cochrane Library. We excluded studies that did not include ACR SLE classification criteria, early-onset controls, that defined late-onset SLE as <50 years of age, or were not written in English. Two authors rated study quality using the Newcastle Ottawa Quality Scale. We used Forest plots to compare odds ratios (95% CI) of cutaneous manifestations by age. Study heterogeneity was assessed using I(2). RESULTS: Overall, 35 studies, representing 11,189 early-onset and 1727 late-onset patients with SLE, met eligibility criteria. The female:male ratio was lower in the late-onset group (5:1 versus 8:1). Most cutaneous manifestations were less prevalent in the late-onset group. In particular, malar rash [OR = 0.43 (0.35, 0.52)], photosensitivity [OR = 0.72 (0.59, 0.88)], and livedo reticularis [OR = 0.33 (0.17, 0.64)] were less common in late-onset patients. In contrast, sicca symptoms were more common [OR = 2.45 (1.91, 3.14)]. The mean Newcastle Ottawa Quality Scale score was 6.3 ± 0.5 (scale: 0-9) with high inter-rater reliability for the score (0.96). CONCLUSIONS: Overall, cutaneous manifestations are less common in late-onset SLE patients, except sicca symptoms. Future studies should investigate etiologies for this phenomenon including roles of immune senescence, environment, gender, and immunogenetics.
OBJECTIVES: Although systemic lupus erythematosus (SLE) most commonly occurs in reproductive-age women, some are diagnosed after the age of 50. Recognizing that greater than one-third of SLE criteria are cutaneous, we undertook a systematic review and meta-analysis to evaluate differences in cutaneous manifestations in early- and late-onset SLEpatients. METHODS: We searched the literature using PubMed, CINAHL, Web of Science, and Cochrane Library. We excluded studies that did not include ACR SLE classification criteria, early-onset controls, that defined late-onset SLE as <50 years of age, or were not written in English. Two authors rated study quality using the Newcastle Ottawa Quality Scale. We used Forest plots to compare odds ratios (95% CI) of cutaneous manifestations by age. Study heterogeneity was assessed using I(2). RESULTS: Overall, 35 studies, representing 11,189 early-onset and 1727 late-onset patients with SLE, met eligibility criteria. The female:male ratio was lower in the late-onset group (5:1 versus 8:1). Most cutaneous manifestations were less prevalent in the late-onset group. In particular, malar rash [OR = 0.43 (0.35, 0.52)], photosensitivity [OR = 0.72 (0.59, 0.88)], and livedo reticularis [OR = 0.33 (0.17, 0.64)] were less common in late-onset patients. In contrast, sicca symptoms were more common [OR = 2.45 (1.91, 3.14)]. The mean Newcastle Ottawa Quality Scale score was 6.3 ± 0.5 (scale: 0-9) with high inter-rater reliability for the score (0.96). CONCLUSIONS: Overall, cutaneous manifestations are less common in late-onset SLEpatients, except sicca symptoms. Future studies should investigate etiologies for this phenomenon including roles of immune senescence, environment, gender, and immunogenetics.
Authors: S Jacobsen; J Petersen; S Ullman; P Junker; A Voss; J M Rasmussen; U Tarp; L H Poulsen; G van Overeem Hansen; B Skaarup; T M Hansen; J Pødenphant; P Halberg Journal: Clin Rheumatol Date: 1998 Impact factor: 2.980
Authors: G S Cooper; C G Parks; E L Treadwell; E W St Clair; G S Gilkeson; P L Cohen; R A S Roubey; M A Dooley Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: M C Hochberg; R E Boyd; J M Ahearn; F C Arnett; W B Bias; T T Provost; M B Stevens Journal: Medicine (Baltimore) Date: 1985-09 Impact factor: 1.889
Authors: Min Zhang; Xuan Fang; Guo-Sheng Wang; Yan Ma; Li Jin; Xiao-Mei Li; Xiang-Pei Li Journal: Inflammopharmacology Date: 2017-02-11 Impact factor: 4.473
Authors: Ashwaq AlE'ed; Pinar Ozge Avar Aydin; Nora Al Mutairi; Alhanouf AlSaleem; Hafize Emine Sonmez; Michael Henrickson; Jennifer L Huggins; Seza Ozen; Sulaiman M Al-Mayouf; Hermine I Brunner Journal: Lupus Sci Med Date: 2018-11-17